Ítem
Solo Metadatos

Estudio de dosis flexibles de paliperidona ER en pacientes con esquizofrenia previamente tratados sin efectividad con otros antipsicóticos*

Mostrar el registro sencillo de la publicación
dc.creatorCordoba Rojas, Rodrigo Nel
dc.creatorCano Romero, Juan Fernando
dc.creatorArango-Dávila, César Augustospa
dc.creatorMiranda, Carlosspa
dc.creatorHolguín, Jorgespa
dc.creatorFernández, Daríospa
dc.creatorMárquez, Miguelspa
dc.creatorLupo, Christianspa
dc.creatorGargoloff, Pedrospa
dc.creatorPetracca, Gustavospa
dc.creatorLucchetti, Césarspa
dc.date.accessioned2020-06-11T13:21:06Z
dc.date.available2020-06-11T13:21:06Z
dc.date.created2012-06spa
dc.description.abstractBACKGROUND: Extended-release (ER) paliperidone is an innovative atypical antipsychotic that allows minimal peak-to-through fluctuations with once-daily dosing.OBJECTIVE: To evaluate effectiveness, safety and tolerability of flexible, once-daily doses of paliperidone ER (3-12 mg/day) in patients with schizophrenia from Argentina and Colombia who had previously failed treatment with other antipsychotic agents.METHODS: The authors conducted a 6-month, open-label, prospective and multicentric study. Effectiveness was assessed with Positive and Negative Syndrome Scale (PANSS) and Personal and Social Performance scale (PSP). Other measures of effectiveness, safety and tolerability, were also conducted.RESULTS: Paliperidone ER 3-12 mg/day improved Positive and Negative Syndrome Scale (PANSS) total scores (primary endpoint) from baseline to study end (p < 0,001). In the PANSS total score, the mean change from baseline (83, 9 units) to end point (53,7 units) was significant (p < 0,001). Flexible doses of paliperidone ER demonstrated a ?20% reduction in the PANSS total score (p<0.001) in almost two-thirds of patients. PSP mean change from baseline (52 units) to end point (85 units) was significant (p < 0,001). Secondary effectiveness assessments, as well as safety and tolerability measures, demonstrated favourable results throughout the study.CONCLUSIONS: Flexible doses of paliperidone ER over 6 months were effective, safe and well tolerated in patients with schizophrenia from Argentina and Colombia.spa
dc.format.mimetypeapplication/pdf
dc.identifier.doihttps://doi.org/10.1016/s0034-7450(14)60009-3
dc.identifier.urihttps://repository.urosario.edu.co/handle/10336/24726
dc.language.isospa
dc.publisherRevista Colombiana de Psiquiatríaspa
dc.relation.citationEndPage356
dc.relation.citationIssueNo. 2
dc.relation.citationStartPage340
dc.relation.citationTitleRevista Colombiana de Psiquiatría
dc.relation.citationVolumeVol. 41
dc.relation.ispartofRevista Colombiana de Psiquiatría, ISSN: , Vol.41, No.2 (2012-06); pp. 340-356spa
dc.relation.urihttps://app.dimensions.ai/details/publication/pub.1007062233spa
dc.rights.accesRightsinfo:eu-repo/semantics/closedAccess
dc.rights.accesoBloqueado (Texto referencial)spa
dc.source.instnameinstname:Universidad del Rosariospa
dc.source.reponamereponame:Repositorio Institucional EdocURspa
dc.subject.keywordPublic Health and Health Servicesspa
dc.subject.keywordMedical and Health Sciencesspa
dc.titleEstudio de dosis flexibles de paliperidona ER en pacientes con esquizofrenia previamente tratados sin efectividad con otros antipsicóticos*spa
dc.typearticleeng
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersion
dc.type.spaArtículospa
Archivos
Colecciones
Artículos